Literature DB >> 16995360

[Probiotics in chronic inflammatory bowel disease].

S Böhm1, W Kruis.   

Abstract

Current data show that probiotics are more effective in preventing the recrudescence of an inflammatory process than in suppressing active disease. This is reflected in the solid evidence for the effect of E. coli Nissle 1917 (Mutaflor) in the maintenance of remission of ulcerative colitis, and of VSL#3 in preventing the recurrence of pouchitis. These indications have since been incorporated in valid guidelines. Initial clinical studies have also provided promising results regarding the efficacy of VSL#3 in preventing pouchitis immediately following proctocolectomy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16995360

Source DB:  PubMed          Journal:  MMW Fortschr Med        ISSN: 1438-3276


  3 in total

Review 1.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

2.  Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN).

Authors:  Harald Matthes; Thomas Krummenerl; Manfred Giensch; Corinna Wolff; Jürgen Schulze
Journal:  BMC Complement Altern Med       Date:  2010-04-15       Impact factor: 3.659

3.  The metabolic profile of Bifidobacterium dentium reflects its status as a human gut commensal.

Authors:  Melinda A Engevik; Heather A Danhof; Anne Hall; Kristen A Engevik; Thomas D Horvath; Sigmund J Haidacher; Kathleen M Hoch; Bradley T Endres; Meghna Bajaj; Kevin W Garey; Robert A Britton; Jennifer K Spinler; Anthony M Haag; James Versalovic
Journal:  BMC Microbiol       Date:  2021-05-24       Impact factor: 3.605

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.